Bullimore Mark A, Saunders Kathryn J, Baraas Rigmor C, Berntsen David A, Chen Zhi, Chia Audrey Wei Lin, Goto So, Jiang Jun, Lan Weizhong, Logan Nicola S, Najjar Raymond P, Polling Jan Roelof, Read Scott A, Woodman-Pieterse Emily C, Széll Noémi, Verkicharla Pavan K, Wu Pei-Chang, Zhu Xiaoying, Loughman James, Nagra Manbir, Phillips John R, Tran Huy D M, Vera-Diaz Fuensanta A, Yam Jason, Liu Yue M, Singh Sarah E, Wildsoet Christine F
College of Optometry, University of Houston, Houston, Texas, United States.
Centre for Optometry and Vision Science, Ulster University, Northern Ireland, United Kingdom.
Invest Ophthalmol Vis Sci. 2025 Sep 2;66(12):39. doi: 10.1167/iovs.66.12.39.
Myopia is recognized as a significant public health problem, particularly in East and Southeast Asia. This has led to the development and evaluation of a range of interventions to slow its progression and delay its onset. Since the publication of the 2019 International Myopia Institute's review of interventions for controlling myopia onset and progression, treatment options have continued to grow in number. This article reviews the efficacy of such interventions under five categories: optical, pharmacological, environmental (behavioral), colored light, and surgical. In summarizing the efficacy of mature technologies, only randomized controlled trials were considered, although such data are very limited for emerging treatments. The overall conclusion is that there are multiple effective interventions in most categories. Further research should aim to understand the mechanisms underlying myopia progression and the modalities that slow its progression in order to develop more effective treatments.
近视被认为是一个重大的公共卫生问题,在东亚和东南亚地区尤为如此。这促使人们开发和评估一系列干预措施,以减缓近视的进展并推迟其发病。自2019年国际近视研究所发表关于控制近视发病和进展的干预措施综述以来,治疗选择的数量持续增加。本文回顾了五类干预措施的疗效:光学、药理学、环境(行为)、色光和手术。在总结成熟技术的疗效时,仅考虑了随机对照试验,尽管新兴治疗方法的此类数据非常有限。总体结论是,大多数类别中都有多种有效的干预措施。进一步的研究应旨在了解近视进展的潜在机制以及减缓其进展的方式,以便开发更有效的治疗方法。